Page 1

nkarta THERAPEUTICS Nkarta Reports Third Quarter 2021 Financial Results and Business Update November 10 , 2021 • Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDS • Successful dosing of NKX019 in patients with B cell malignancies ; initial Phase 1 clinical trial data expected in 2022 SOUTH SAN FRANCISCO , Calif . , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- Nkarta , Inc. ( Nasdaq : NKTX ) , a biopharmaceutical company developing engineered natural killer ( NK ) cell therapies to treat cancer , today reported financial results for the third quarter ended September 30 , 2021 . " We are on track to achieve key data milestones for our two co - lead programs in 2022 with the recently announced dosing of patients in our clinical trial of NKX019 and further progress in our first - in - human clinical trial of NKX101 , " said Paul J. Hastings , President and Chief Executive Officer of Nkarta . " We continue to be excited about the early advancements we are making in our collaboration with CRISPR Therapeutics on CD70 engineered CAR NK cell and NK plus T cell candidates , and we look forward to sharing updates on potential clinical applications of multiple platform enhancements during the SITC annual meeting . " RECENT UPDATES NKX101 • In October 2021 , Nkarta updated guidance to the first half of 2022 for when it expects to announce initial clinical data from its ongoing Phase 1 clinical trial of NKX101 in patients with relapsed / refractory acute myeloid leukemia ( AML ) and higher risk myelodysplastic syndromes ( MDS ) . NKX019 • In October 2021 , Nkarta announced the dosing of the first patients in the Phase 1 clinical trial evaluating NKX019 in CD19 + advanced B cell malignancies . Initial data are expected in 2022 . Manufacturing • Nkarta is producing the clinical supply of NKX019 at its recently commissioned in - house cGMP clinical manufacturing facility in South San Francisco , California . • Nkarta entered a lease agreement to establish a new 88,000 square foot combined manufacturing facility and company headquarters . Once operational , the manufacturing facility will increase Nkarta's manufacturing footprint with capacity to produce materials for potential pivotal trials and commercial launch of Nkarta's engineered NK cell therapy products . Pipeline and Platform • Nkarta is announcing updates on multiple platform and pipeline enhancements at the Society for Immunotherapy of Cancer 36th Annual Meeting and Pre - Conference Program ( SITC 2021 ) November 10 - 13 , 2021. Preclinical data on CRISPR / Cas9 genome engineering and CD70 chimeric antigen receptor ( CAR ) targeting are being jointly presented with CRISPR Therapeutics . In addition , Nkarta will be presenting data on donor selection in next generation NK cell development programs and novel methods for scaling the expansion of engineered NK cells . THIRD QUARTER 2021 FINANCIAL HIGHLIGHTS • Cash and Cash Equivalents : As of September 30 , 2021 , Nkarta had cash , cash equivalents , restricted cash and short - term investments of $ 259.8 million . • R & D Expenses : Research and development expenses were $ 16.6 million for the third quarter of 2021. Non - cash share - based compensation expense included in R & D expense was $ 1.7 million for the third quarter of 2021 . • G & A Expenses : General and administrative expenses were $ 5.8 million for the third quarter of 2021. Non - cash share - based compensation expense included in G & A expense was $ 2.0 million for the third quarter of 2021 . • Net Loss . Net loss was $ 22.4 million , or $ 0.68 per basic and diluted share , for the third quarter of 2021 . FINANCIAL GUIDANCE